Compensation available if eligible for participation
Fill out the personal health questions below to see if you meet the basic study requirements. Additional eligibility criteria apply. Your answers will be recorded, but your information will only be used for the purposes of this study to determine your eligibility.
FAQS
The investigational treatment, RE104, is being developed as a potential new treatment for postpartum depression (PPD). It’s a psychedelic, similar to psilocybin. It’s being studied to see if it can reduce depressive symptoms for people with PPD.
If you decide to participate, you will be randomly assigned (like a coin toss) to receive either the low or high dose of the investigational treatment.
The study will last up to 53 days. You will have a screening period, where the study site will ask you questions and make sure you qualify. You’ll have an 8-hour treatment visit, where you will receive a one-time injection of the investigational treatment and be monitored. You will have follow-up visits both in-person and virtually, where the study staff will check up on how you are doing. Additional study information will be provided to you.
This study is called the RECONNECT study. It’s sponsored by Reunion.
The study will compare the effects of 2 different doses of a study drug, RE104 — a low dose and a high dose. At the study clinic, you will receive a one-time injection of the investigational treatment. The study team will be on-site to closely monitor you during the entire treatment, which can last up to 10 hours. They will continue to track your health and PPD symptoms for another 4 weeks, both in-person and virtually, to see how you are doing. The entire study may last up to 53 days.
Women who have given birth within the past 12 months may be eligible to participate if they are between the ages of 18–45, are not breastfeeding (or are willing to stop entirely), and began experiencing symptoms of PPD in the second or third trimester of pregnancy or within four weeks after giving birth. Symptoms may include, but are not limited to, feelings of sadness, hopelessness or guilt; excessive worrying; or loss of interest in activities you once enjoyed.
Yes. To support your commitment to the study, you will receive monetary compensation for your time and reimbursement for your travel expenses. All study-related care costs will be covered in full. Additionally, you may be eligible to receive other assistance during treatment, such as financial aid towards buying infant formula.
No. You may not take part in this study if you are breastfeeding, pregnant, think that you may be pregnant, or are trying to get pregnant. You must have stopped breastfeeding before taking part in the study (your baby must already be permanently weaned) and you must not resume breastfeeding, even after the study has ended. Support may be available for women who need help accessing formula while enrolled in the study.
Please note: 1nHealth may store your data in a confidential and secure database. That personal information will never be shared or sold with any other persons or organizations not associated with 1nHealth. 1nHealth may/will use personal information to contact you directly by phone and/or email for matters related to potential participation in clinical trials, studies, and projects for which the potential participant may qualify. See our Privacy Policy for more details. Legal Notice & Terms of Service.